Home › Bladder Cancer › Arizona › Tucson
Bladder Cancer clinical trials in Tucson, AZ
4 studies for Bladder Cancer are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- University of Arizona - Cancer Center, Tucson
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- The University of Arizona Cancer Center - North Campus, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- The University of Arizona Cancer Center, Tucson
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY36 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA25 studies
- Baltimore, MD24 studies
- Philadelphia, PA23 studies
- Edison, NJ23 studies
- St. Louis, MO22 studies
- Chicago, IL21 studies
Other studies in Tucson
- Obesity20 studies
- Breast Cancer18 studies
- Non-Small Cell Lung Cancer18 studies
- Overweight17 studies
- Metastatic Cancer14 studies
- Type 2 Diabetes13 studies
- Cancer (all types)12 studies
- Prostate Cancer12 studies
- Colorectal Cancer11 studies
- Cardiovascular Disease11 studies
- Steatotic Liver Disease10 studies
- Acute Myeloid Leukemia10 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.